Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Inclusion criteria

• 1.18-80 years old, gender not limited. 2.The patient voluntarily joined this study and signed informed consent 3.ECOG score is 0 or 1 4.Expected survival period ≥ 2 years. 5.Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer 6.There are assessable lesions that meet the RECIST 1.1 criteria 7. Enough organ function

Exclusion criteria

• Received systemic anti-tumor therapy 4 weeks before starting the study treatment
• The toxicity and/or complications of previous anti-tumor treatments have not recovered to NCI-CTCAE ≤ 1 level
• Subjects known or suspected to have interstitial pneumonia
• Individuals with any active, known or suspected autoimmune diseases
• There are clinical symptoms or diseases of the heart that have not been well controlled
• Diagnosed with any other malignant tumor
• Subjects who have experienced severe infections within 28 days prior to their first medication use
• History of immunodeficiency
• Use of attenuated live vaccine within 28 days prior to the first study medication
• Have undergone major surgery within 28 days prior to the first administration of medication